Posaconazole or isavuconazole as sole or predominant antifungal therapy for COVID-19-associated mucormycosis. A retrospective observational case series

The surge of COVID-19 associated Mucormycosis (CAM) in India during the second wave of COVID-19 led to lack of availability of amphotericin B(AmB). We retrospectively evaluated the outcome in 28 consecutive patients with CAM who received posaconazole (PCZ) or isavuconazole (ISVCZ) as sole or predomi...

Descripción completa

Detalles Bibliográficos
Autores principales: Soman, Rajeev, Chakraborty, Sourabh, Joe, Geethu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: The Author(s). Published by Elsevier Ltd on behalf of International Society for Infectious Diseases. 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993494/
https://www.ncbi.nlm.nih.gov/pubmed/35405351
http://dx.doi.org/10.1016/j.ijid.2022.04.009

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8993494/
https://www.ncbi.nlm.nih.gov/pubmed/35405351
http://dx.doi.org/10.1016/j.ijid.2022.04.009

Ejemplares similares